进一步改善电休克治疗（ECT）的认知效应特征：研究氨甲酰化促红细胞生成素的理由。

Further improving the cognitive effect profile of electroconvulsive therapy (ECT): the case for studying carbamylated erythropoietin.

作者信息

Kellner C H, Adams D A, Benferhat A

机构信息

Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, United States.

出版信息

Med Hypotheses. 2015 Mar;84(3):258-61. doi: 10.1016/j.mehy.2015.01.007. Epub 2015 Jan 14.

DOI:10.1016/j.mehy.2015.01.007

PMID:25649853

Abstract

Electroconvulsive therapy (ECT) remains the most effective acute treatment for severe depression and several other psychiatric illnesses. However, its use has been limited by concerns about cognitive adverse effects. ECT may cause temporary cognitive impairment in some patients, typically anterograde amnesia for 1-2 weeks after a course of treatment, and circumscribed retrograde amnesia. These cognitive effects largely disappear within days to weeks after treatment. Efforts to find a pharmacological agent to reduce the cognitive effects of ECT have largely been unsuccessful, with the possible exception of thyroid hormone. We review the literature on pharmacological attempts to attenuate ECT's cognitive effects, and propose a novel neuroprotective and neurotrophic agent, carbamylated erythropoietin (CEPO), for this indication.

摘要

电休克疗法（ECT）仍然是治疗重度抑郁症和其他几种精神疾病最有效的急性治疗方法。然而，其应用一直受到对认知不良反应担忧的限制。ECT可能会在一些患者中导致暂时性认知障碍，通常在一个疗程后会出现1至2周的顺行性遗忘，以及局限性逆行性遗忘。这些认知影响在治疗后的数天至数周内大多会消失。寻找一种能减轻ECT认知影响的药物的努力大多没有成功，甲状腺激素可能是个例外。我们回顾了关于减轻ECT认知影响的药物尝试的文献，并针对这一适应症提出了一种新型神经保护和神经营养药物——氨甲酰化促红细胞生成素（CEPO）。